Zachary Rosenthal
CEO, Founder Birdwood Therapeutics
Zach Rosenthal, PhD, is the Founder and CEO of Birdwood Therapeutics. Zach earned his PhD in Chemistry & Chemical Biology at Harvard, where his research focused on developing precision medicine therapeutics for genetic forms of dementia. At Birdwood, Zach is pioneering the first high-throughput, lysate-compatible platform for discovering proximity-inducing small molecules.
Seminars
Tuesday 28th October 2025
Panel Discussion: Overcoming the Common Pitfalls in Early Workflows for the Discovery of Induced Proximity Drugs
3:00 pm
Monday 27th October 2025
Optimizing Drug Discovery with the Development of an Ultra High-Throughput, Lysate-Compatible Induced Proximity Screening System
9:30 am
- Advantages of cell lysate-based screening over recombinant protein screens
- Adapting high-throughput combinatorial chemistry to improve upon their sensitivity, enable their compatibility with cell lysates, and allow their discovery of induced proximity small molecules
- Sharing proof-of-concept data (either full scale, or if not yet available, model system) for Birdwood’s platform
